Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 188

1.

Sacubitril/valsartan: beyond natriuretic peptides.

Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC.

Heart. 2017 Jul 8. pii: heartjnl-2017-311295. doi: 10.1136/heartjnl-2017-311295. [Epub ahead of print] Review.

PMID:
28689178
2.

Risk Factors for Nonadherence to Antihypertensive Treatment.

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M.

Hypertension. 2017 Jun;69(6):1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729. Epub 2017 May 1.

PMID:
28461599
3.

Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.

Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, Roux S, Swedberg K; ENABLE Investigators and Committees.

JACC Heart Fail. 2017 May;5(5):317-326. doi: 10.1016/j.jchf.2017.02.021.

PMID:
28449795
4.

Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?

Gulsin GS, Shetye A, Khoo J, Swarbrick DJ, Levelt E, Lai FY, Squire IB, Arnold JR, McCann GP.

BMC Cardiovasc Disord. 2017 Apr 8;17(1):98. doi: 10.1186/s12872-017-0529-y.

5.

Circular RNAs in heart failure.

Devaux Y, Creemers EE, Boon RA, Werfel S, Thum T, Engelhardt S, Dimmeler S, Squire I; Cardiolinc network.

Eur J Heart Fail. 2017 Jun;19(6):701-709. doi: 10.1002/ejhf.801. Epub 2017 Mar 27. Review.

PMID:
28345158
6.

Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study.

Singh A, Greenwood JP, Berry C, Dawson DK, Hogrefe K, Kelly DJ, Dhakshinamurthy V, Lang CC, Khoo JP, Sprigings D, Steeds RP, Jerosch-Herold M, Neubauer S, Prendergast B, Williams B, Zhang R, Hudson I, Squire IB, Ford I, Samani NJ, McCann GP.

Eur Heart J. 2017 Apr 21;38(16):1222-1229. doi: 10.1093/eurheartj/ehx001.

PMID:
28204448
7.

Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure.

Suzuki T, Israr MZ, Heaney LM, Takaoka M, Squire IB, Ng LL.

Clin Chem. 2017 Apr;63(4):880-886. doi: 10.1373/clinchem.2016.265140. Epub 2017 Feb 9.

PMID:
28183728
8.

Proenkephalin, Renal Dysfunction, and Prognosis in Patients With Acute Heart Failure: A GREAT Network Study.

Ng LL, Squire IB, Jones DJ, Cao TH, Chan DC, Sandhu JK, Quinn PA, Davies JE, Struck J, Hartmann O, Bergmann A, Mebazaa A, Gayat E, Arrigo M, Akiyama E, Sabti Z, Lohrmann J, Twerenbold R, Herrmann T, Schumacher C, Kozhuharov N, Mueller C; GREAT Network.

J Am Coll Cardiol. 2017 Jan 3;69(1):56-69. doi: 10.1016/j.jacc.2016.10.038.

PMID:
28057251
9.

Comparison of global myocardial strain assessed by cardiovascular magnetic resonance tagging and feature tracking to infarct size at predicting remodelling following STEMI.

Shetye AM, Nazir SA, Razvi NA, Price N, Khan JN, Lai FY, Squire IB, McCann GP, Arnold JR.

BMC Cardiovasc Disord. 2017 Jan 5;17(1):7. doi: 10.1186/s12872-016-0461-6.

10.

Geographic variations in the PARADIGM-HF heart failure trial.

Kristensen SL, Martinez F, Jhund PS, Arango JL, Bĕlohlávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ.

Eur Heart J. 2016 Nov 1;37(41):3167-3174. Epub 2016 Jun 28.

11.

Remote ischaemic conditioning and remodelling following myocardial infarction: current evidence and future perspectives.

Vanezis AP, Rodrigo GC, Squire IB, Samani NJ.

Heart Fail Rev. 2016 Sep;21(5):635-43. doi: 10.1007/s10741-016-9560-9.

12.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators.

N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.

13.

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees.

Circ Heart Fail. 2016 Jan;9(1). pii: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.

14.

Global myocardial strain assessment by different imaging modalities to predict outcomes after ST-elevation myocardial infarction: A systematic review.

Shetye A, Nazir SA, Squire IB, McCann GP.

World J Cardiol. 2015 Dec 26;7(12):948-60. doi: 10.4330/wjc.v7.i12.948.

15.

Plasma growth hormone is a strong predictor of risk at 1 year in acute heart failure.

Bhandari SS, Narayan H, Jones DJ, Suzuki T, Struck J, Bergmann A, Squire IB, Ng LL.

Eur J Heart Fail. 2016 Mar;18(3):281-9. doi: 10.1002/ejhf.459. Epub 2015 Dec 15.

16.

Distinct and complementary roles for α and β isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose.

Jackson R, Brennan S, Fielding P, Sims MW, Challiss RA, Adlam D, Squire IB, Rainbow RD.

Br J Pharmacol. 2016 Mar;173(5):870-87. doi: 10.1111/bph.13399. Epub 2016 Feb 8.

17.

Circulating microRNAs and Outcome in Patients with Acute Heart Failure.

Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, Vodovar N, Sadoune M, Samuel JL, Thum T, Solal AC, Laribi S, Plaisance P, Wagner DR, Mebazaa A, Devaux Y; GREAT network.

PLoS One. 2015 Nov 18;10(11):e0142237. doi: 10.1371/journal.pone.0142237. eCollection 2015.

18.

Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.

Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJ, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees.

J Am Coll Cardiol. 2015 Nov 10;66(19):2059-71. doi: 10.1016/j.jacc.2015.08.878.

19.

Growth hormone for risk stratification and effects of therapy in acute myocardial infarction.

Ng LL, Bhandari SS, Sandhu JK, Quinn PA, Squire IB, Davies JE, Struck J, Bergmann A, Jones DJ.

Biomarkers. 2015;20(6-7):371-5. doi: 10.3109/1354750X.2015.1093031. Epub 2015 Nov 2.

PMID:
26525661
20.

Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure.

Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S, Griffin S, Allgar V, Jones L, Nabb S, Harvey I, Squire I, Murphy J, Greenstone M.

Health Technol Assess. 2015 Sep;19(75):1-120. doi: 10.3310/hta19750.

Supplemental Content

Loading ...
Support Center